X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs GLENMARK PHARMA - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. GLENMARK PHARMA WOCKHARDT LTD./
GLENMARK PHARMA
 
P/E (TTM) x 16.9 13.6 123.6% View Chart
P/BV x 1.7 3.8 45.0% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 WOCKHARDT LTD.   GLENMARK PHARMA
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-16
GLENMARK PHARMA
Mar-16
WOCKHARDT LTD./
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs2,0001,262 158.5%   
Low Rs706672 105.1%   
Sales per share (Unadj.) Rs403.7270.6 149.2%  
Earnings per share (Unadj.) Rs29.524.9 118.5%  
Cash flow per share (Unadj.) Rs42.434.4 123.1%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs323.4151.3 213.7%  
Shares outstanding (eoy) m110.51282.16 39.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.43.6 93.8%   
Avg P/E ratio x45.938.9 118.1%  
P/CF ratio (eoy) x31.928.1 113.7%  
Price / Book Value ratio x4.26.4 65.5%  
Dividend payout %08.0 0.0%   
Avg Mkt Cap Rs m149,509272,778 54.8%   
No. of employees `0007.410.0 73.6%   
Total wages/salary Rs m9,44313,782 68.5%   
Avg. sales/employee Rs Th6,048.67,614.9 79.4%   
Avg. wages/employee Rs Th1,280.21,374.8 93.1%   
Avg. net profit/employee Rs Th441.5700.2 63.1%   
INCOME DATA
Net Sales Rs m44,61476,340 58.4%  
Other income Rs m970356 272.2%   
Total revenues Rs m45,58476,696 59.4%   
Gross profit Rs m5,03814,172 35.6%  
Depreciation Rs m1,4262,691 53.0%   
Interest Rs m1,0121,789 56.6%   
Profit before tax Rs m3,57010,048 35.5%   
Minority Interest Rs m-650-   
Prior Period Items Rs m60-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2553,028 8.4%   
Profit after tax Rs m3,2577,019 46.4%  
Gross profit margin %11.318.6 60.8%  
Effective tax rate %7.130.1 23.7%   
Net profit margin %7.39.2 79.4%  
BALANCE SHEET DATA
Current assets Rs m39,90659,096 67.5%   
Current liabilities Rs m18,42340,018 46.0%   
Net working cap to sales %48.225.0 192.7%  
Current ratio x2.21.5 146.7%  
Inventory Days Days9075 120.3%  
Debtors Days Days98119 82.4%  
Net fixed assets Rs m35,83239,075 91.7%   
Share capital Rs m553282 195.8%   
"Free" reserves Rs m30,37030,281 100.3%   
Net worth Rs m35,73942,703 83.7%   
Long term debt Rs m16,54224,873 66.5%   
Total assets Rs m79,522111,026 71.6%  
Interest coverage x4.56.6 68.4%   
Debt to equity ratio x0.50.6 79.5%  
Sales to assets ratio x0.60.7 81.6%   
Return on assets %5.47.9 67.7%  
Return on equity %9.116.4 55.4%  
Return on capital %8.717.5 49.4%  
Exports to sales %11.643.3 26.8%   
Imports to sales %4.57.4 60.0%   
Exports (fob) Rs m5,17733,044 15.7%   
Imports (cif) Rs m1,9905,672 35.1%   
Fx inflow Rs m7,58936,945 20.5%   
Fx outflow Rs m2,87861,066 4.7%   
Net fx Rs m4,711-24,122 -19.5%   
CASH FLOW
From Operations Rs m7163,449 20.8%  
From Investments Rs m-8,182-8,802 93.0%  
From Financial Activity Rs m2,5436,986 36.4%  
Net Cashflow Rs m-4,923934 -527.2%  

Share Holding

Indian Promoters % 74.5 48.3 154.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 6.9 33.3%  
FIIs % 7.7 34.4 22.4%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 10.5 146.7%  
Shareholders   67,757 56,727 119.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  ALEMBIC LTD  ALKEM LABORATORIES  AJANTA PHARMA  

Compare WOCKHARDT LTD. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Aug 23, 2017 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. - WYETH LTD COMPARISON

COMPARE WOCKHARDT LTD. WITH

MARKET STATS